Denis Zeyer

Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff.

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France.

Bionext SA develops software applications for pharmaceuticals and biotechnology companies. The firm integrates big data and cloud computing, and OMICS data through computer simulations for enabling to visualize, understand, and correct actions of drugs in human cells, as well as in drug discovery processes. The company was founded by Laurent-Philippe Albou and Serge Henri Albou in 2009 and is headquartered in Strasbourg, France.

Inoviem Scientific SAS offers preclinical and clinical services that use cutting-edge proprietary technologies to speed up drug-development. Its services include preclinical and drug discovery, patient stratification and biomarkers clinical development. The company was founded by Pierre Eftekhari in 2011 and is headquartered in Strasbourg, France.

Capital Grand Est SAS (Capital Grand Est) formerly known as Alsace Capital, is a private equity firm headquartered in France. Founded in 2012, the firm is wholly owned by Region Grand Est of France and has offices in Schiltigheim, France.

DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France.

Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020.

Alderaan Biotechnology SAS operates as preclinical stage firm, that develops monoclonal antibodies for the treatment of cancer. The company was founded by Daniel Olive and Armand Bensussan on July 17, 2017 and is headquartered in Paris, France.

AdBio Partners SAS (AdBio Partners) is a venture capital firm founded in 2015. The firm is headquartered in Paris, France.

GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France.

Luxfold S.A. designs and engineers protein structures. It offers protein three-dimensional structure. The company is headquartered in Luxembourg.

Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.

Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France.